Seattle-based Presage Biosciences, a spinoff from the Fred Hutchinson Cancer Research Center, is making some leadership changes.
CEO Caitlin Cameron has resigned, and is being replaced on an interim basis by Jim Towne, an investor in the company who was briefly president of Microsoft in its early days. Nathan Caffo, Presage’s vice president of business development, will take on additional responsibility as interim president, according to founder Jim Olson.
Presage, founded by Olson at the Hutch in November 2008, has raised more than $5 million to develop a tool to help drugmakers predict which drugs are likely to succeed in clinical trials.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
